SMALL CELL LUNG CARCINOMA

This early-stage study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3. It is for adults with advanced lung, prostate, or gut cancers that have not responded to other treatments. The main goals are to check safety, find the right dose,…

This study tests a new drug called LY4175408 in people with advanced lung, endometrial, or breast cancer that has spread. The drug is designed to target and kill cancer cells while sparing healthy ones. The goal is to check safety, how the drug moves through the body, and whether…

This study is testing whether a precise type of radiation called stereotactic radiosurgery (SRS) can help people with small cell lung cancer that has spread to the brain. About 62 adults with up to 20 brain tumors will receive SRS, and researchers will track how many are alive af…

This study tests whether adding an experimental drug called cirtuvivint to standard chemotherapy (irinotecan) can help people with small cell lung cancer that has come back after initial treatment. About 42 adults whose cancer has progressed after at least one prior therapy will …

This early-phase study tests a new treatment for advanced lung cancer that uses a person's own immune cells, modified to better recognize and attack cancer cells. The treatment, called iC9-GD2.CAR.IL-15 T cells, combines antibodies and T cells to target a protein (GD2) found on s…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests whether giving a higher total dose of radiation, split into two smaller treatments each day, can help people with limited-stage small cell lung cancer live longer without the cancer growing. About 300 participants will receive standard chemotherapy plus one of th…

This study tests the drug durvalumab as a follow-up treatment for people with limited-stage small cell lung cancer whose cancer has not grown after chemotherapy and radiation. About 70 adults in Spain will receive durvalumab to see how safe it is and how well it works in real-wor…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study is for people with extensive-stage small cell lung cancer whose disease got worse after initial treatment with immunotherapy and chemotherapy. Researchers are testing new drugs, either alone or combined with pembrolizumab, to see if they can shrink tumors or slow the c…

This study tests a drug called onvansertib in people with small cell lung cancer whose cancer did not respond to or came back after chemotherapy. The drug blocks a protein that cancer cells need to repair themselves. About 37 participants will take the drug to see if it shrinks t…

This study tests a new drug, BI 764532 (obrixtamig), in adults with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to treatment. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dos…

This study tests an experimental drug called PF-08046050 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to stick to cancer cells and kill them. The main goal is to check safety and find the right dose. About 914 adults wi…

This study is testing a new imaging agent called 89Zr-DFO-SC16.56 to see if it can safely and effectively highlight small cell lung cancer tumors on PET/CT scans. The agent targets a protein called DLL3 found on these cancer cells. About 53 people with small cell lung cancer or r…

This study looks at whether people with advanced small cell lung cancer can be safely monitored at home after receiving the drug tarlatamab, instead of staying in the hospital. About 70 adults will take part, and researchers will track how many days they spend in the hospital ver…

This study is collecting information and biological samples from 730 adults newly diagnosed with lung cancer. Researchers want to see how patients respond to treatments in everyday medical practice, not just in strict clinical trials. The goal is to better understand the disease …

This study aims to understand lung cancer better in people diagnosed at age 45 or younger. Researchers will collect blood and tumor samples from 500 participants to look for genetic changes and other markers. The goal is to find new ways to treat or detect this disease earlier.

This study is testing whether a team of different specialists (like surgeons, cancer doctors, and geriatricians) can create better, personalized treatment plans for older adults (ages 60-90) with lung cancer. The goal is to see if this team approach helps people live longer witho…